Alto Neuroscience (ANRO) Times Interest Earned (2023 - 2026)
Alto Neuroscience (ANRO) posted Times Interest Earned of -$49.79 for Q1 2026, down 170.07% sequentially from $71.06 in Q4 2025, and down 535.3% YoY from $11.44 in Q1 2025.
Alto Neuroscience (ANRO) Times Interest Earned (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Times Interest Earned for 4 years, with the latest figure at -$49.79 in Q1 2026.
- Quarterly Times Interest Earned fell 535.3% year-over-year to -$49.79 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$119.18 (down 241.01% YoY) and the FY2025 annual result came in at -$1.27, up 30.62% from the prior year.
- Times Interest Earned slipped to -$49.79 in Q1 2026 per ANRO's latest filing, from $71.06 in the prior quarter.
- Over five years, Times Interest Earned peaked at $16997.0 in Q4 2024 and troughed at -$54.11 in Q3 2024.
- A 4-year average of $1301.1 and a median of -$22.23 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2026: Times Interest Earned surged 14636.03% in 2024, then tumbled 535.3% in 2026.
- Over 4 years, Times Interest Earned stood at $115.34 in 2023, then soared by 14636.03% to $16997.0 in 2024, then slumped by 99.58% to $71.06 in 2025, then plunged by 170.07% to -$49.79 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$49.79, $71.06, and -$0.01 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.22 |
| Mar 31, 2026 | -49.79 |
| Dec 31, 2025 | 71.06 |
| Sep 30, 2025 | -0.01 |
| Jun 30, 2025 | -0.05 |
| Mar 31, 2025 | -7.84 |
| Dec 31, 2024 | 16,997.00 |
| Sep 30, 2024 | -54.11 |
| Jun 30, 2024 | -45.85 |
| Mar 31, 2024 | -41.58 |
| Dec 31, 2023 | 115.34 |
| Sep 30, 2023 | -24.30 |
| Jun 30, 2023 | -22.81 |
| Mar 31, 2023 | -22.23 |